Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Isoray, Inc. (ISR)

NYSE American - Nasdaq Real Time Price. Currency in USD
Add to watchlist
0.3011-0.0064 (-2.08%)
At close: 04:00PM EDT
0.3200 +0.02 (+6.28%)
After hours: 05:18PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.3075
Open0.3028
Bid0.3011 x 45100
Ask0.3150 x 1100
Day's Range0.2986 - 0.3200
52 Week Range0.2500 - 0.9400
Volume162,887
Avg. Volume367,191
Market Cap42.731M
Beta (5Y Monthly)0.99
PE Ratio (TTM)N/A
EPS (TTM)-0.0400
Earnings DateFeb 07, 2022 - Feb 11, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.08
  • Zacks

    IsoRay (ISR) Reports Q3 Loss, Lags Revenue Estimates

    IsoRay (ISR) delivered earnings and revenue surprises of 0% and 7.62%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Isoray Announces Record Third Quarter Fiscal 2022 Financial Results

    Revenue Increased 12% Year-Over-YearRecord Non-Prostate Brachytherapy Revenue Increased 28% Year-Over-Year RICHLAND, Wash., May 10, 2022 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy, today announced its financial results for the third quarter of fiscal 2022 ended March 31, 2022. Revenue for the third quarter of fiscal 2022 grew 12% to $2.91 million versus $2.60 million in the prior year comparable period. The Company’s co

  • Zacks

    Oncternal Therapeutics (ONCT) Reports Q1 Loss, Tops Revenue Estimates

    Oncternal Therapeutics (ONCT) delivered earnings and revenue surprises of -5.26% and 6.57%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Advertisement
Advertisement